The holiday week may have slowed the markets, but the pot business didn’t take any time off. We’ve got the goods on who missed out in the Alberta deal, and the return of the Friday Flier.
It was a snooze out there today, but we have a new US retail listing and a few developments on the day that we finally see the Canadian marijuana bill passed… sort of. Plus: Abcann Global vs. Invictus MD.
Note: This one was scheduled to be published last night, was delayed in production. This morning, Aleafia Health (ALEF.V) is up $0.10 to $0.90 on 3 million shares, Pascal Biosciences (PAS.V) is up $0.02 to $0.49 on 4 million shares, and Scythian Bioscience (SCYB.V) is down $0.06 to $3.11 on 75k shares.
The slightest of oil bumps got the Canadian mid-caps spending like drunken sailors, the market hates it. Meanwhile, mining deals are so cheap that flush companies are making all-cash offers at 50% premium.
Two new pot deals launched on a down day, so we’re having a look at what’s working and what isn’t in this extended trip.
Deutsche Bank and citi implicated in Oz banking scam, and a curious Canopy Growth disclosure has the Datajam looking in its crystal ball.
The Pilbara bounce: the only gold area play working shakes off the irrational exuberance and settles into regular delusion. OGI OGI OGI! OY! OY! OY! Is Organigram low-key undervalued? Want to be a high binding investment banker? It’s easier than you think.
Trump tariffs so Trudeau tries a toothless trade war, an unlikely leader on the TSX, and Pilbara becomes yesterday’s news overnight; a temperamental gold market thinks Novo’s bulk sample is the bunk. BONUS: Paleoplacer treasure map.
A maddening mystery inspires manhunt in Mississauga. The oil market didn’t fall, so much as it was tripped. Leaks have us wondering about Kinder’s commitment and the projects profitability in an uncontrollable environment, and we found another Friday flyer.